DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer. In Vitro DHODH-IN-23 (Compound A; 72 h) inhibits acute myeloid leukemia cells proliferation. DHODH-IN-23 (0.1-3 μM; 72 h) induces CDllb expression in THP-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: U937, HL-60, THP-1, KG-1 and MV411 Concentration: Incubation Time: 72 h Result: Inhibited cell growth with GI 50 s of 2.4, 2.5, 2.5, 3.5 and 7.6 μM against U937, THP-1, MV411 HL-60 and KG-1, respectively. RT-PCRCell Line: THP-1 cells Concentration: 72 h Incubation Time: 0.1, 1 and 3 μM Result: Induced CDllb mRNA expression. In Vivo DHODH-IN-23 (Compound A; 30 mg/kg; oral; twice daily for 21 days) shows antitumor activity in MV411 mouse xenograft model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MV411 mouse xenograft model Dosage: 30 mg/kg Administration: Oral administration, twice daily for 21 days Result: Demonstrated significant anti-tumor activity both as a single agent and in combination with Cytarabine at 20 mg/kg with tumor growth inhibitions of 37 and 73% respectively. Form:Solid